We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Conversion chemotherapy with capecitabine and oxaliplatin for colorectal cancer with potentially resectable liver metastases: A phase II, open-label, single-arm study.
- Authors
Li, Yong; Li, Guo-Xin; Chu, Zhong-Hua; Hao, Chun-Yi; Jiang, Zhi-Wei; Chen, Huan-Qiu; Lin, Jian-Jiang; Li, De-Chuan; Hu, Bing; Wang, Xi-Shan; Lin, Feng
- Abstract
<bold>Aim: </bold>The aim of this is study is to assess the efficacy and safety of conversion capecitabine plus oxaliplatin (XELOX) in Chinese patients with potentially resectable colorectal liver metastases (CLMs).<bold>Patients and Methods: </bold>Thirty patients (median age 57.5 years) with potentially resectable CLMs were treated with XELOX in a single-arm, open-label, nonrandomized, multicenter clinical trial.<bold>Results: </bold>The objective response rate in the 30 patients was 40% (95% confidence interval: 22.7%-59.4%), and the rate of conversion to resectable CLMs was 43.3%. Patients who underwent liver resection (n = 11) had a longer median progression-free survival and overall survival than those who did not. XELOX showed an acceptable safety profile.<bold>Conclusion: </bold>XELOX may effectively convert potentially resectable CLM into resectable CLM, providing survival benefits with a favorable safety profile.<bold>Clinical Trials.gov Identifier: </bold>NCT 00997685.
- Subjects
CANCER chemotherapy; OXALIPLATIN; COLON cancer treatment; LIVER metastasis; DRUG efficacy; PREVENTION; THERAPEUTICS; ANTINEOPLASTIC agents; CLINICAL trials; COLON tumors; COMPARATIVE studies; RESEARCH methodology; LIVER tumors; MEDICAL cooperation; ORGANOPLATINUM compounds; RECTUM tumors; RESEARCH; TUMOR classification; EVALUATION research; TREATMENT effectiveness; DIAGNOSIS
- Publication
Journal of Cancer Research & Therapeutics, 2018, Vol 14, Issue 4, p772
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/jcrt.JCRT_738_17